Long-term Metformin Use is Associated with Decreased Risk of Breast Cancer

Overview

Journal Diabetes Care

Specialty Endocrinology

Date 2010 Mar 20

PMID 20299480

Citations 212

Authors

Michael Bodmer

Christian Meier

Stephan Krahenbuhl

Susan S Jick

Christoph R Meier

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate whether use of oral hypoglycemic agents is associated with an altered breast cancer risk in women.

Research Design And Methods: Using the U.K.-based General Practice Research Database, we conducted a nested case-control analysis among 22,621 female users of oral antidiabetes drugs with type 2 diabetes. We evaluated whether they had an altered risk of breast cancer in relation to use of various types of oral hypoglycemic agents. Case and control patients with a recorded diagnosis of type 2 diabetes were matched on age, calendar time, and general practice, and the multivariate conditional logistic regression analyses were further adjusted for use of oral antidiabetes drugs, insulin, estrogens, smoking BMI, diabetes duration, and HbA1c (A1C).

Results: We identified 305 case patients with a recorded incident diagnosis of breast cancer. The mean +/- SD age was 67.5 +/- 10.5 years at the time of the cancer diagnosis. Long-term use of >or=40 prescriptions (>5 years) of metformin, based on 17 exposed case patients and 120 exposed control patients, was associated with an adjusted odds ratio of 0.44 (95% CI 0.24-0.82) for developing breast cancer compared with no use of metformin. Neither short-term metformin use nor use of sulfonylureas or other antidiabetes drugs was associated with a materially altered risk for breast cancer.

Conclusions: A decreased risk of breast cancer was observed in female patients with type 2 diabetes using metformin on a long-term basis.

Citing Articles

Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits.

Yip J, Chiang G, Lee I, Lehming-Teo R, Dai K, Dongol L Int J Mol Sci. 2025; 26(1.

PMID: 39796218 PMC: 11719901. DOI: 10.3390/ijms26010364.

Risk of Incident Cancer in Veterans with Diabetes Who Use Metformin Versus Sulfonylureas.

Abdallah M, de Oliveira B, DuMontier C, Orkaby A, Nussbaum L, Gaziano M J Cancer Prev. 2025; 29(4):140-147.

PMID: 39790228 PMC: 11706726. DOI: 10.15430/JCP.24.012.

Clinical Effect of Treatment with Metformin for Type 2 Diabetes on Non-Small Cell Lung Cancer Patients Undergoing Immunotherapy: A Retrospective Study.

Wang Y, Sun Y, Hu J, Ma H Int J Gen Med. 2025; 17:6595-6604.

PMID: 39759894 PMC: 11699848. DOI: 10.2147/IJGM.S495449.

Assessing the antitumor effects of metformin on ovarian clear cell carcinoma.

Takemori S, Morisada T, Osaka M, Watanabe M, Tajima A, Tanigaki S Hum Cell. 2024; 37(5):1462-1474.

PMID: 39115639 DOI: 10.1007/s13577-024-01116-4.

Discovering Potential in Non-Cancer Medications: A Promising Breakthrough for Multiple Myeloma Patients.

Al-Odat O, Nelson E, Budak-Alpdogan T, Jonnalagadda S, Desai D, Pandey M Cancers (Basel). 2024; 16(13).

PMID: 39001443 PMC: 11240591. DOI: 10.3390/cancers16132381.

References

Kaye J, Derby L, Quinn M, Jick H . The incidence of breast cancer in the General Practice Research Database compared with national cancer registration data. Br J Cancer. 2000; 83(11):1556-8. PMC: 2363417. DOI: 10.1054/bjoc.2000.1493. View

Landman G, Kleefstra N, van Hateren K, Groenier K, Gans R, Bilo H . Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2009; 33(2):322-6. PMC: 2809274. DOI: 10.2337/dc09-1380. View

Goodwin P, Ennis M, Pritchard K, Trudeau M, Koo J, Madarnas Y . Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002; 20(1):42-51. DOI: 10.1200/JCO.2002.20.1.42. View

Jick S, Kaye J, Vasilakis-Scaramozza C, Garcia Rodriguez L, Ruigomez A, Meier C . Validity of the general practice research database. Pharmacotherapy. 2003; 23(5):686-9. DOI: 10.1592/phco.23.5.686.32205. View

Wood L, Martinez C . The general practice research database: role in pharmacovigilance. Drug Saf. 2004; 27(12):871-81. DOI: 10.2165/00002018-200427120-00004. View

Del Giudice M, Fantus I, Ezzat S, McKeown-Eyssen G, Page D, Goodwin P . Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat. 1998; 47(2):111-20. DOI: 10.1023/a:1005831013718. View

Evans J, Donnelly L, Emslie-Smith A, Alessi D, Morris A . Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330(7503):1304-5. PMC: 558205. DOI: 10.1136/bmj.38415.708634.F7. View

Anisimov V, Berstein L, Egormin P, Piskunova T, Popovich I, Zabezhinski M . Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol. 2005; 40(8-9):685-93. DOI: 10.1016/j.exger.2005.07.007. View

Bowker S, Majumdar S, Veugelers P, Johnson J . Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006; 29(2):254-8. DOI: 10.2337/diacare.29.02.06.dc05-1558. View

10.

Lipscombe L, Goodwin P, Zinman B, McLaughlin J, Hux J . Increased prevalence of prior breast cancer in women with newly diagnosed diabetes. Breast Cancer Res Treat. 2006; 98(3):303-9. DOI: 10.1007/s10549-006-9166-3. View

11.

Zakikhani M, Dowling R, Fantus I, Sonenberg N, Pollak M . Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006; 66(21):10269-73. DOI: 10.1158/0008-5472.CAN-06-1500. View

12.

Govindarajan R, Ratnasinghe L, Simmons D, Siegel E, Midathada M, Kim L . Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol. 2007; 25(12):1476-81. DOI: 10.1200/JCO.2006.07.2777. View

13.

Dowling R, Zakikhani M, Fantus I, Pollak M, Sonenberg N . Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007; 67(22):10804-12. DOI: 10.1158/0008-5472.CAN-07-2310. View

14.

Pollack M . Insulin, insulin-like growth factors, insulin resistance, and neoplasia. Am J Clin Nutr. 2008; 86(3):s820-2. DOI: 10.1093/ajcn/86.3.820S. View

15.

Xue F, Michels K . Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr. 2008; 86(3):s823-35. DOI: 10.1093/ajcn/86.3.823S. View

16.

Brauchli Y, Jick S, Curtin F, Meier C . Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: A population based case-control study. J Am Acad Dermatol. 2008; 58(3):421-9. DOI: 10.1016/j.jaad.2007.11.023. View

17.

Goodwin P . Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions?. J Clin Oncol. 2008; 26(6):833-4. DOI: 10.1200/JCO.2007.14.7132. View

18.

Meier C, Kraenzlin M, Bodmer M, Jick S, Jick H, Meier C . Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008; 168(8):820-5. DOI: 10.1001/archinte.168.8.820. View

19.

Lipscombe L, Goodwin P, Zinman B, McLaughlin J, Hux J . The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat. 2007; 109(2):389-95. DOI: 10.1007/s10549-007-9654-0. View

20.

Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A . The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem. 2008; 114(1):23-37. DOI: 10.1080/13813450801969715. View